A phase 2 trial from the University of Miami evaluated whether combining iberdomide with carfilzomib, daratumumab, and dexamethasone could induce deep responses—including MRD-negativity—in patients with...
A randomized phase III study evaluated whether a carfilzomib-based triplet regimen could improve depth of response and progression-free survival compared with standard bortezomib-based therapy in patients...
A new real-world study evaluates whether GLP-1 receptor agonists, commonly prescribed for diabetes and obesity, are associated with a reduced risk of progression from monoclonal gammopathy of undetermined...
In a multicenter US study of patients with relapsed/refractory multiple myeloma receiving commercial ciltacabtagene autoleucel, investigators examined whether rapid peak CAR T-cell expansion and absolute...
A phase 1b–2 trial published in The New England Journal of Medicine evaluated the combination of two bispecific antibodies, talquetamab and teclistamab, for patients with relapsed or refractory multiple...
Optimal management of multiple myeloma is evolving with the introduction of new and emerging therapeutic options. Ajay K. Nooka, MD, MPH, discusses these treatment options and updates to the standards of...
The researchers analyzed 569 patients with multiple myeloma, stratified patients on the basis of their percentage of CD56-expressing clonal MM cells, and then evaluated patient outcomes based on this...
To determine whether patients with multiple myeloma have a suboptimal antibody response to vaccination against COVID-19, researchers evaluated 35 patients with multiple myeloma who were diagnosed with...
To examine the prognostic value of flow cytometry plus PET/CT scanning for detecting minimal residual disease in patients with multiple myeloma, researchers conducted an observational cohort study of 94...
For their study, the researchers aimed to clarify the mechanisms behind racial and ethnic disparities in multiple myeloma disease outcomes by investigating the demographic, clinical, and molecular features...
